SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549
                                   FORM 10-Q





[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended JUNE 30, 1997

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD
FROM _______TO _______

Commission File No. 0-26690

                          ELANTEC SEMICONDUCTOR, INC.
             (Exact Name of registrant as specified in its charter)

           Delaware                                    77-0408929
--------------------------------------------------------------------------------
(State or other jurisdiction of                     (I.R.S. Employer
incorporation or organization)                     Identification No.)

675 Trade Zone Boulevard, Milpitas, California             95035
--------------------------------------------------------------------------------
(Address of principal executive offices)                 (Zip Code)

Registrant's telephone number, including area code: (408) 945-1323
--------------------------------------------------------------------------------

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  Registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.           Yes X        No
                                                -----       -----

As of July 28, 1997,  8,978,874 shares of the Registrant's  Common Stock,  $0.01
par value, were issued and outstanding.

<PAGE>   2
                                               TABLE OF CONTENTS



<TABLE>
<CAPTION>
                                                                                                 Page
                                                                                                 ----
<S>              <C>                                                                               <C>
PART I           FINANCIAL INFORMATION

    Item 1.      Condensed Consolidated Financial Statements  . . . . . . . . . . . . . . . . .    3

                 Notes to Condensed Consolidated Financial Statements . . . . . . . . . . . . .    6

    Item 2.      Management's Discussion and Analysis of Financial Condition
                    and Results of Operations  . .  . . . . . . . . . . . . . . . . . . . . . .    8

    Item 3.      Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . .    11


PART II          OTHER INFORMATION

    Item 4.      Submission of Matters to a Vote of Security Holders .. . . . . . . . . . . . .    12

    Item 6.      Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . . . . .    12

                 Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    13
</TABLE>

<PAGE>   3
PART I.  FINANCIAL INFORMATION
Item 1.   Condensed Consolidated Financial Statements



                           ELANTEC SEMICONDUCTOR, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                      (In thousands, except per share data)
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                    Three Months Ended    Nine Months Ended
                                                         June 30,             June 30,
                                                  --------------------   --------------------
                                                    1997        1996       1997        1996
                                                  --------    --------   --------    --------
<S>                                               <C>         <C>        <C>         <C>
Net revenues ..................................   $  9,195    $  9,782   $ 25,690    $ 27,946
Cost of revenues ..............................      5,223       4,627     14,737      13,246
                                                  --------    --------   --------    --------
   Gross profit ...............................      3,972       5,155     10,953      14,700


Operating expenses:
   Research and development ...................      1,787       1,582      4,723       4,741
   Marketing, sales, general and administrative      2,196       2,248      6,479       6,324
                                                  --------    --------   --------    --------
   Total operating expenses ...................      3,983       3,830     11,202      11,065
                                                  --------    --------   --------    --------


Income (loss) from operations .................        (11)      1,325       (249)      3,635
Interest and other, net .......................        123         111        326         332
                                                  --------    --------   --------    --------
Income before taxes ...........................        112       1,436         77       3,967
Provision for taxes on income .................         14         113         10         310
                                                  --------    --------   --------    --------

Net income ....................................   $     98    $  1,323   $     67    $  3,657
                                                  ========    ========   ========    ========

Net income per share ..........................   $   0.01    $   0.14   $   0.01    $   0.39
                                                  ========    ========   ========    ========

Shares used in computing per share amounts ....      9,239       9,448      9,271       9,337
                                                  ========    ========   ========    ========
</TABLE>




See accompanying notes to the condensed consolidated financial statements.




<PAGE>   4


                           ELANTEC SEMICONDUCTOR, INC.
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (In thousands)
<TABLE>
<CAPTION>
                                                                     June 30,      Sept. 30,
                                                                       1997         1996 (1)
                                                                   ----------      ---------
                                   (Unaudited)
<S>                                                                  <C>             <C>
Current assets:
   Cash and cash equivalents .....................................   $ 9,153         $ 9,377
   Short-term investments ........................................     5,964           6,663
   Accounts receivable, net ......................................     3,350           4,175
   Inventories ...................................................     7,190           6,475
   Prepaid expenses and other current assets .....................       556             554
                                                                     -------         -------
Total current assets .............................................    26,213          27,244

Property and equipment, net ......................................     8,999           7,360
Other assets, net ................................................       557             642
                                                                     =======         =======
Total assets .....................................................   $35,769         $35,246
                                                                     =======         =======

Liabilities and stockholders' equity:
Current liabilities:
   Accounts payable and accrued liabilities ......................   $ 4,167         $ 5,335
   Deferred revenue ..............................................     2,670           3,143
   Current portion of long-term debt and capital lease obligations     1,422           1,128
                                                                     -------         -------
Total current liabilities ........................................     8,259           9,606

Long-term debt and capital lease obligations .....................     3,249           1,566

Stockholders' equity .............................................    24,261          24,074
                                                                     =======         =======
Total liabilities and stockholders' equity .......................   $35,769         $35,246
                                                                     =======         =======
</TABLE>

(1)   The  information  in this column was derived  from the  Company's  audited
      consolidated financial statements at September 30, 1996.





See accompanying notes to the condensed consolidated financial statements.





<PAGE>   5
                           ELANTEC SEMICONDUCTOR, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (In thousands)
                                   (Unaudited)


<TABLE>
<CAPTION>
                                Nine Months Ended
                                    June 30,
                                                             -------------------
                                                               1997       1996
                                                             -------    --------
<S>                                                         <C>        <C>
Operating activities:
Net income ..............................................   $    67    $  3,657

Adjustments   to  reconcile  net  income  to  net  cash  provided  by  operating
activities:
      Depreciation and amortization .....................     1,456       1,211
      Changes in operating assets and liabilities:
          Accounts receivable ...........................       825        (945)
          Inventories ...................................      (715)     (1,345)
          Prepaid expenses and other current assets .....        (2)        213
          Accounts payable and accrued liabilities ......    (1,168)        620
          Deferred revenue ..............................      (473)        210

Net cash provided by (used in) operating activities .....       (10)      3,621

Investing activities:
Sale/maturity (purchase) of available-for-sale securities       699      (3,451)
Purchase of property and equipment ......................      (143)     (1,994)
Decrease in other assets ................................        85         262
                                                            -------    --------
Net cash provided by (used in) investing activities .....       641      (5,183)

Financing activities:
Payments on capital lease and other debt ................      (975)       (698)
Issuance of common stock ................................       120       8,510
                                                            -------    --------
Net cash provided by (used in)financing activities ......      (855)      7,812

Increase (decrease) in cash and cash equivalents ........      (224)      6,250
Cash and cash equivalents at beginning of period ........     9,377       6,009
                                                            =======    ========
Cash and cash equivalents at end of period ..............   $ 9,153    $ 12,259
                                                            =======    ========


Supplemental disclosures of cash flow information:
Lease and installment financing for capital equipment ...   $ 2,952    $  1,219

Interest paid ...........................................   $   193    $    147

Taxes paid ..............................................   $    50    $    185

</TABLE>



See accompanying notes to the condensed consolidated financial statements.





<PAGE>   6

ELANTEC SEMICONDUCTOR, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1.       BASIS OF PRESENTATION

The unaudited condensed  consolidated  financial statements included herein have
been  prepared  by the  Company  pursuant  to the rules and  regulations  of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. In the opinion of management, all adjustments (consisting
of normal recurring items)  considered  necessary for a fair  presentation  have
been  included.  The results of  operations  for the three and nine months ended
June 30, 1997 are not  necessarily  indicative of the results to be expected for
the entire  year.  These  consolidated  financial  statements  should be read in
conjunction  with the  consolidated  financial  statements and the notes thereto
included  in the  Company's  Annual  Report  on Form  10-K  for the  year  ended
September 30, 1996.

The  Company's  fiscal  year end is the  Sunday  closest  to  September  30. The
Company's  fiscal  quarters end on the Sunday closest to the end of the calendar
quarter.  For  convenience,  the Company has indicated  that its quarters end on
December 31, March 31, June 30 and September 30.

NOTE 2.       USE OF ESTIMATES

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes.
Actual results could differ from those estimates.

NOTE 3.       CASH AND CASH EQUIVALENTS

The Company  considers all highly liquid  investments with an original  maturity
(at the date of purchase) of three months or less to be the  equivalent  of cash
for purposes of balance sheet and statement of cash flows presentation. Cash and
cash equivalents are carried at cost, which approximates market value.

NOTE 4.       SHORT-TERM INVESTMENTS

The  Company's  policy is to  invest  in  various  short-term  instruments  with
investment  grade credit ratings.  Generally such  investments  have contractual
maturities of less than one year.  All of the Company's  marketable  investments
are  classified  as   "available-for-sale"   and  the  Company   classifies  its
available-for-sale  portfolio as available for use in its current operations. At
June 30, 1997, there was no significant difference between the fair market value
and the underlying cost of such securities.

NOTE 5.       INVENTORIES

Inventories  are  stated  at the lower of  standard  cost  (first-in,  first-out
method) or market and consist of the following balances in thousands:


<TABLE>
<CAPTION>
                                                    June 30,       Sept.30,
                                                      1997           1996
                                                     ------        ------
     <S>                                             <C>           <C>
     Raw materials ..................................$  828        $  800
     Work-in-process ................................ 4,840         4,266
     Finished goods ................................. 1,522         1,409
                                                     ------        ------
                                                     $7,190        $6,475
                                                     ======        ======
</TABLE>





<PAGE>   7

NOTE 6.       NET INCOME PER SHARE

Net income  per share is  calculated  based on the  weighted  average  number of
common and dilutive  common  share  equivalents  outstanding  using the treasury
stock  method.   Common  share  equivalents   reflect  the  dilutive  effect  of
outstanding stock options. Dilutive securities include options and warrants.

In February 1997, the Financial  Accounting standards Board issued Statement No.
128, Earning per Share, which is required to be adopted on December 31, 1997. At
that time,  the Company will be required to change the method  currently used to
compute  earnings  per share and to  restate  all prior  periods.  Under the new
requirements for calculating  primary earnings per share, the dilutive effect of
stock options will be excluded.  There is no impact expected in primary earnings
per share for the third quarter ended June 30, 1997.  Primary earnings per share
is expected to increase  for the third  quarter  ended June 30, 1996 by $0.01per
share.  The impact of Statement No. 128 on fully diluted  earnings per share for
these quarters is not expected to be material.



<PAGE>   8


ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

Except for the historical information contained herein, matters discussed in the
Form  10-Q  may  contain  forward-looking  statements  that  involve  risks  and
uncertainties.  The Company's actual future results could differ materially from
those discussed here. Factors that could cause or contribute to such differences
include,  but are not limited to, those discussed in this section, as well as in
the section  entitled  "Business" in the Company's 1996 Form 10-K filed with the
Securities and Exchange Commission.

The table below states the income  statement items for the three and nine months
ended June 30, 1997 and 1996 as a  percentage  of net  revenues and provides the
percentage change in absolute dollars from the previous year:


<TABLE>
<CAPTION>
                                     Three Months      Three Months     Dollar %     Nine Months       Nine Months    Dollar %
                                        Ended             Ended          Change        Ended             Ended         Change
                                    --------------------------------------------- ----------------------------------------------
                                     June 30, 1997     June 30, 1996               June 30, 1997     June 30, 1996
                                    --------------    --------------              --------------    --------------
<S>                                      <C>               <C>          <C>           <C>               <C>           <C>
Net revenues                             100.0%            100.0%        -6%          100.0%            100.0%         -8%
Cost of revenues                          56.8%             47.7%        13%           57.4%             47.4%         11%
   Gross profit                           43.2%             52.7%       -23%           42.6%             52.6%        -26%


Operating expenses:
   Research and development               19.4%             16.2%        13%           18.4%             17.0%          0%
   Marketing, sales, general
        and administrative                23.9%             23.0%        -2%           25.2%             22.6%          3%
</TABLE>

RESULTS  OF  OPERATIONS  - During  the third  fiscal  quarter  of 1997,  Elantec
generated net revenues of $9.2  million,  a decrease of 6% from the $9.8 million
reported in the same quarter of the previous  year. For the first nine months of
fiscal 1997 net  revenues  were $25.7  million,  a decrease of 8% from the $28.0
million  reported in the  corresponding  period of fiscal 1996. This decrease is
attributed  to a shift in sales mix to lower priced  products and overall  lower
average selling prices due to competitive  market  pressures,  offset in part by
slightly higher unit sales volumes.

Cost of goods sold increased to 57% of net sales for the third quarter of fiscal
1997 compared to 47% for the third quarter of fiscal 1996. During the first nine
months of fiscal 1997, cost of goods sold increased to 57% from 47% reported for
the  corresponding  period of fiscal 1996.  The  resulting  increase in cost and
corresponding  decrease in gross margin for each comparable  period is primarily
due to increased unfavorable  manufacturing  variances and lower average selling
prices due to a more competitive market environment.

Research and  development  expenses  increased  by $0.2 million  compared to the
dollar  amounts  reported  in the third  quarter of fiscal  1996  largely due to
increased  expenditures for mask sets,  silicon and other materials.  During the
first  nine  months of fiscal  1997,  research  and  development  expenses  were
relatively  flat when compared the  corresponding  period of fiscal 1996. If the
Company moves to the "SOI"  technology as contemplated  (see discussion  below),
absolute dollar research and development expenses are expected to increase.

Marketing, selling and general and administrative expenses for the third quarter
were  relatively  flat  compared  to the dollar  amounts  reported  in the third
quarter of fiscal 1996. During the first nine months of fiscal 1997,  marketing,
selling and general and  administrative  expenses increased by $0.2 million from
that reported for the corresponding  period of fiscal 1996. This increase is due
to provisions for bad debts recorded in the first quarter if fiscal 1997.

The Company's provision for income taxes for the third quarter of fiscal 1997 is
lower than the statutory  rate,  principally due to the benefit of net operating
loss carryforwards  offset by alternative  minimum taxes and foreign withholding
taxes.

On July 4, 1997 the Company announced that it would discontinue its military and
commercial  hybrid  product.  This product line  accounted  for 8.7% and 8.0% of
product  revenues  during the third quarter and nine months ended June 30, 1997,
respectively.  Orders for these  discontinued  products will be accepted through
December 20, 1997 with last  shipments  from the factory by March 20, 1998.  The
company  expects higher  revenues and gross margins from last-buy  orders during
the first  quarter of fiscal  1998.  However,  the  company  does not expect the
discontinuance  of this product line to have a material  impact on the Company's
fourth quarter 1997 or annual 1998 results from operations.

<PAGE>   9

FACTORS AFFECTING FUTURE RESULTS - Elantec's operating results have been, and in
the future  may be,  subject to  fluctuations  due to a wide  variety of factors
including  the  timing  of or  delays  in new  product  and  process  technology
announcements  and  product  introductions  by the  Company or its  competitors,
competitive pricing pressures,  fluctuations in manufacturing yields, changes in
the mix of product sold,  availability  and costs of raw materials,  reliance on
subcontractors, the cyclical nature of the semiconductor industry, industry-wide
wafer  processing  capacity,   political  and  economic  conditions  in  various
geographic   areas,   and  costs   associated   with  other   events,   such  as
underutilization  or expansion of  production  capacity,  intellectual  property
disputes, litigation, or environmental regulation.

The  semiconductor   industry  is  highly  cyclical  and  has  been  subject  to
significant economic  fluctuations at various times that have been characterized
by rapidly fluctuating product demand,  periods of over and under capacity,  and
accelerated   erosion  of  average   selling   prices.   A  material  change  in
industry-wide  production  capacity,  shift in industry capacity toward products
competitive with the Company's  products,  rapidly  fluctuating demand, or other
factors could result in a rapid decline in product pricing or unit volumes which
could adversely affect the Company's operating results.

From time to time, the Company has experienced production difficulties that have
caused delivery delays and quality problems.  There can be no assurance that the
Company will not experience  manufacturing  problems and product delivery delays
in the  future as a result  of,  among  other  things,  changes  to its  process
technologies, ramping production, installing new equipment at its facilities and
constructing new facilities in Milpitas, California.

The Company is  reconsidering an extensive  production  expansion at its primary
manufacturing  facility in Milpitas,  California.  The expansion,  if completed,
will result in a  significant  increase in fixed and operating  expenses.  These
additional expenses could reduce gross margins.  Specifically, the Company would
anticipate  incurring  substantial  operating  costs  and  depreciation  expense
relating to the expanded  facility  before  production of substantial  volume is
achieved.  If  revenue  levels do not  increase  sufficiently  to  offset  these
additional  expense levels,  or if the Company is unable to achieve gross margin
greater than or  comparable  to the Company's  current  products,  the Company's
future  results of operations  could be adversely  impacted.  Additionally,  the
project  faces a number of  substantial  risks  including,  but not  limited to,
project termination,  delays in construction, cost overruns, equipment delays or
shortages, manufacturing start-up or process problems, or difficulties in hiring
key managers and technical personnel.

New products, process technology and start-up costs associated with the Milpitas
wafer  fabrication  facility will require  significant  research and development
expenditures.  However,  there can be no assurance that the Company will be able
to develop and introduce new products in a timely manner, that new products will
gain market  acceptance  or that new process  technologies  can be  successfully
implemented.  If the  Company  is unable to  develop  new  products  in a timely
manner,  and to sell them at gross margins  comparable to the Company's  current
products, the future results of operations could be adversely impacted.

Part of the Company's  future bipolar product  development  strategy may include
the  development  of  an  alternative  form  of   silicon-on-insulator   ("SOI")
technology  called  bonded  wafers.  The Company  currently  believes  that,  if
successful,  the bonded wafer technology could provide technologically  advanced
products at a lower cost than the  current  dielectric  isolation  complementary
bipolar  technology.  However,  there  can be no  assurance  that  bonded  wafer
technology can be  successfully  accomplished in a timely manner or that it will
provide  the  desired   improvements  over  the  Company's  current  technology.
Significant  delays or  cancellation  of the  development  of the  bonded  wafer
technology  and/or  manufacturing  problems  associated  with  transferring  the
Company's  current product line to this technology would have a material adverse
affect on the Company's business and results of operations.  In addition, delays
or cancellation of the development of this technology could adversely affect the
Company's new product development program.

<PAGE>   10

The   semiconductor   industry  is  extremely  capital   intensive.   To  remain
competitive,  the Company  must  continue  to invest in  advanced  manufacturing
equipment  and  process  technologies.  If the  decision  to move ahead with the
aforementioned  capacity  expansion  and  technology  improvement  is made,  the
Company  may be  required  to expend  approximately  $12.3  million  in  capital
expenditures.  Additionally,  the  Company  anticipates  significant  continuing
capital  expenditures in the next several years.  There can be no assurance that
the  Company  will not be  required  to seek  financing  to satisfy its cash and
capital needs or that such financing will be available on terms  satisfactory to
the  Company.  If such  financing  is required  and if such  financing  were not
available  on  terms  satisfactory  to the  Company,  its  operations  would  be
materially adversely affected.

The semiconductor  industry is characterized by vigorous  protection and pursuit
of intellectual property rights or positions, which have resulted in significant
and often protracted and expensive litigation. In recent years, there has been a
growing   trend  of  companies  to  resort  to   litigation   to  protect  their
semiconductor  technology from unauthorized use by others.  The Company believes
its products do not infringe upon any valid  patents.  However,  there can be no
assurance that the Company's  position in these matters will prevail.  There can
be  no  assurance  that  additional  future  claims  alleging   infringement  of
intellectual  property  rights will not be asserted  against  the  Company.  The
intellectual property claims that have been made, or may be asserted against the
Company in the future,  could  require that the Company  discontinue  the use of
certain processes or cease the manufacture, use and sale of infringing products.
Additionally,  the Company may incur significant litigation costs and damages to
develop  noninfringing  technology.  There can be no assurance  that the Company
would  be able to  obtain  such  licenses  on  acceptable  terms  or to  develop
noninfringing technology without a material adverse effect on the Company.

The  Company  is  subject  to a variety  of  regulations  related  to  hazardous
materials  used in its  manufacturing  process.  Any  failure by the  Company to
control  the use of, or to  restrict  adequately  the  discharge  of,  hazardous
materials  under present or future  regulations  could subject it to substantial
liability or could cause its manufacturing operations to be suspended.

The Company's Common Stock has experienced substantial price volatility and such
volatility   may   occur  in  the   future,   particularly   as  a   result   of
quarter-to-quarter  variations in the actual or anticipated financial results of
the  Company,  the  companies  in the  semiconductor  industry or in the markets
served by the  Company,  or  announcements  by the  Company  or its  competitors
regarding  new  product  introductions.   In  addition,  the  stock  market  has
experienced  extreme price and volume fluctuations that have affected the market
price of many  technology  companies'  stock in  particular.  These  factors may
adversely affect the price of the Common Stock.

<PAGE>   11

LIQUIDITY  AND CAPITAL  RESOURCES - During the first nine months of fiscal 1997,
the Company financed its operations  primarily from existing cash and short-term
investment  balances.  At June 30,  1997,  the Company had  approximately  $15.1
million of cash and short-term investments.

Net cash used in operating activities was $10,000 for the nine months ended June
30, 1997, and consisted  primarily of decreases in accounts  payable and accrued
liabilities  and  an  increase  in  inventory,   offset  by   depreciation   and
amortization expenses and a decrease in accounts receivable.

Cash  provided by  investing  activities  was $641,000 for the nine months ended
June 30, 1997. This increase was primarily attributed to net sales/maturities of
available-for-sale  securities  during the nine-month period ended June 30, 1997
and consisted primarily of commercial paper and short-term corporate notes.

Capital  expenditures  were $3.1 million during the nine-month period ended June
30, 1997 of which $3.0 million was leased using the Company's nonrevolving lease
line of credit.  The  Company  expects  to fund an  additional  $0.5  million of
capital  in the  fourth  quarter of fiscal  1997 the  majority  of which will be
leased  using  existing   credit   facilities.   At  June  30,  1997  there  was
approximately  $6.2  million  available  credit  under lease  lines.  There were
outstanding commitments to purchase capital assets of approximately $0.5 million
at June 30, 1997.

Historically,  the Company has generated  cash through  operations and financing
activities  in an  amount  sufficient  to fund  its  requirements.  The  Company
believes that cash on hand, cash anticipated to be generated from operations and
cash obtained through  borrowing or leasing  arrangements  will be sufficient to
meet the Company's working capital and capital expenditure requirements at least
through the next twelve months.  Any major change in the nature of the Company's
business,  such as those  mentioned  in the previous  section,  could change the
Company's capital  requirements.  To the extent the Company requires  additional
cash,  there can be no  assurance  that the Company  will be able to obtain such
financing on terms favorable to the Company, or at all.

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable




<PAGE>   12



PART II - OTHER INFORMATION

ITEM 4. - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the quarter ended
June 30, 1997.

ITEM 6. - EXHIBITS AND REPORTS ON FORM 8-K

(a)       The following exhibits are filed as part of this report:

         Exhibit 11.1 - Statement re Computation of Per Share Earnings
         Exhibit 27.1 - Financial Data Schedule

(b)       Reports on Form 8-K:

         The Company  filed no reports on Form 8-K during the quarter ended June
         30, 1997.

<PAGE>   13




SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

ELANTEC SEMICONDUCTOR, INC.
(Registrant)



Date: August 13, 1997                     By: /s/ David O'Brien
                                          ---------------------
                                          David O'Brien
                                          President, Chief Executive Officer
                                          (Duly authorized officer and principal
                                          financial officer)




<PAGE>   14

                                                 EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit

<S>         <C>
11.1        Statement re Computation of Per Share Earnings
27.1        Financial Data Schedule
</TABLE>